How to Use anti-obesity in a Sentence

anti-obesity

adjective

• These are key questions in the debate over the new anti-obesity drugs.
  — Heather Wilhelm, National Review, 22 Feb. 2024
• In fact, people have a wide range of responses to anti-obesity medicines.
  — Emily Mullin, WIRED, 1 July 2024
• Oz has spoken favorably about anti-obesity drugs in the past.
  — Youri Benadjaoud, ABC News, 11 Dec. 2024
• And doctors say people shouldn't take these anti-obesity medications just to drop a few pounds.
  — Karen Weintraub, USA TODAY, 22 Mar. 2023
• For type 2 diabetics, this is used for long-term weight management and is an anti-obesity drug.
  — Amber Smith, Discover Magazine, 25 Sep. 2023
• It's also believed that yerba mate has anti-obesity effects.
  — Sarah Bence, Verywell Health, 10 June 2026
• Weight Watchers) and Noom are now prescribing these anti-obesity meds as part of their weight loss programs.
  — Lipi Roy, Md, Forbes, 29 Feb. 2024
• But fewer people are turning to surgery with the advent of new anti-obesity medications.
  — Eric Berger, ArsTechnica, 11 Apr. 2025
• Watch to see how closely these disparities are reflected in who gets access to new anti-obesity treatments.
  — Caitlin Owens, Axios, 13 Sep. 2024
• The timing was of interest to those who are waiting to see if there’s any chance of popular anti-obesity drugs being included.
  — Claire Bugos, Verywell Health, 30 Sep. 2024
• An outspoken critic of popular anti-obesity drugs, Kennedy seems to have tempered his views on the topic.
  — Swapna Venugopal Ramaswamy, USA TODAY, 29 Jan. 2025
• Surveys show nearly half of employer insurance plans cover the anti-obesity drugs.
  — Ken Alltucker, USA Today, 30 Apr. 2026
• Large pharma companies like Roche and Pfizer are also working on their own anti-obesity drugs.
  — Bruce Gil, Quartz, 4 Sep. 2024
• Should Medicare cover the new generation of anti-obesity drugs?
  — Heather Wilhelm, National Review, 22 Feb. 2024
• In other words, the more effective anti-obesity drugs become, the more insurance providers might realize their value.
  — Laura Hensley, Verywell Health, 11 Jan. 2024
• Shares rose 5% as the anti-obesity drugmaker posted third-quarter earnings and revenue that topped estimates .
  — Sarah Min, CNBC, 30 Oct. 2025
• Safety problems in the 1990s with the anti-obesity treatment known as fen-phen, which had to be withdrawn from the market, were also fresh in their minds.
  — Amanda Seitz, Fortune, 28 Dec. 2023
• Last year, the influential group added anti-obesity medications as part of its guidelines for treating obesity in kids ages 12 and up.
  — Marina Kopf, NBC News, 21 Feb. 2024
• Medicare hasn't released an estimate of how many Americans might qualify for the anti-obesity drugs under the bridge program.
  — Ken Alltucker, USA Today, 29 June 2026
• Obesity has become a massive global health crisis, but the emergence of novel anti-obesity drugs has been a powerful tool in curbing the pandemic.
  — Isabella Backman, Hartford Courant, 12 June 2026
• Goldman Sachs projects global anti-obesity drug sales will reach $105 billion by 2030.
  — Ken Alltucker, USA Today, 1 Apr. 2026
• Since Wegovy has only been on the market as an anti-obesity drug since 2021, there’s some uncertainty about its long-term effects.
  — Sarah Sloat, Health, 30 Mar. 2023
• The paper showed that people taking the drug lost on average 15 percent of their body weight—a level of weight loss practically unheard-of for an anti-obesity medicine.
  — Matt Reynolds, WIRED, 7 July 2023
• Sharp said the program is collaborating with community health centers in the city and with Froedtert Health to get the word out about the anti-obesity program.
  — Sarah Volpenhein, Journal Sentinel, 26 July 2024
• Those who purchase their own health insurance are unlikely to get coverage for anti-obesity drugs such as Wegovy and Saxenda.
  — Ken Alltucker, USA TODAY, 1 Dec. 2024
• The chances of your employer covering an anti-obesity drug depends on its size — bigger organizations are much more likely to offer the benefit than smaller ones.
  — Tami Luhby, CNN, 9 Oct. 2024
• Today, it is approved for anti-obesity purposes and brings in billions annually for its maker, Novo Nordisk.
  — Elsa Ohlen, CNBC, 30 Dec. 2025
• Some analysts estimate that anti-obesity medications could grow into a $100 billion industry by the end of the decade.
  — Ashley Capoot, CNBC, 18 Jan. 2025
• Though Novo was first on the market with its anti-obesity medication Wegovy, Lilly's sales for the weight loss drug Zepbound have surged.
  — Ken Alltucker, USA Today, 21 July 2026
• The first group was prescribed semaglutide, while the second was prescribed anti-obesity drugs that weren’t GLP-1 receptor agonists.
  — Aria Bendix, NBC News, 15 Apr. 2024